Prime
[Illustrations] Selective Capital, Targeted Deals, and a Tightened Public-Market Bar: How 2026 Is Shaping M&A and IPOs
2026-02-09
[Illustrations] 2026 Policy and Geopolitics as Catalysts: IRA Pricing Mechanics and BIOSECURE’s Supply Chain Decoupling
2026-02-09
[Illustrations] Radiopharmaceuticals in 2026: Alpha Emitters, Industrial Scale, and the Supply Chain as Strategy
2026-02-09
[Illustrations] 2026 TechBio Stress Test: Can AI Deliver Real Drugs as Recursion, Insilico Medicine and Schrödinger Take Center Stage
2026-02-06
[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms
2026-02-05
[Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector
2026-01-30
[Illustrations] The Global and Taiwan Orphan Drug Market Heads Into 2026 With New Rules, New Prices, and New Pressure Points
2026-01-29
Tiny RNA Fragments Emerge as Powerful Drivers of Prostate Cancer Growth and Therapeutic Opportunity
2026-01-29
[Illustrations] Global Blockbuster Drug Landscape Shifts in 2026: Keytruda Defends No. 1, “Diabesity” Rivals Surge, IRA Price Caps Take Effect
2026-01-22
LATEST
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California





